Perspectives on Drug Development in Early ADPKD

Perspectives on Drug Development in Early ADPKD - PMC

Future directions in ADPKD including “bridging biomarkers,” such as microRNAs, proteomics, and proteins in urinary extracellular vesicles, are promising.

Perspectives on Drug Development in Early ADPKD - PubMed

Perspectives on Drug Development in Early ADPKD. Clin J Am Soc Nephrol. 2022 Oct;17(10):1555-1558. doi: 10.2215/CJN.05190422. Epub 2022 Aug 23.

Perspectives on Drug Development in Autosomal Recessive Poly...

Here, we summarize key aspects discussed in a session on drug development in ARPKD that took place during the 2021 PKD Regulatory Summit.

Perspectives on Drug Development in Early ADPKD - ResearchGate

PDF | On Aug 23, 2022, Djalila Mekahli and others published Perspectives on Drug Development in Early ADPKD | Find, read and cite all the research you need ...

Current Challenges and Perspectives on Developing a Clinical Trial ...

Autosomal dominant polycystic kidney disease (ADPKD) workshop outcome: A common ADPKD protocol design. DDI, drug-drug interaction; htTKV, height-adjusted total ...

Polycystic Kidney Disease Drug Development: A Conference Report

Currently, only one drug (tolvaptan) has been approved by regulatory agencies as disease-modifying therapy for ADPKD, but, given its mechanism of action and ...

Perspectives on Drug Development in Early ADPKD - OUCI

Chebib, Autosomal dominant polycystic kidney disease: Core curriculum 2016, Am J Kidney Dis, № 67, с. · Chebib, Assessing risk of rapid progression in autosomal ...

Impact on Industry and Patients: Polycystic Kidney Disease ...

A single drug, called tolvaptan, was under development, but many questions remained regarding how to best design adequate and efficient clinical trials for this ...

PKD Outcomes Consortium (PKDOC)

Perspectives on Drug Development in Autosomal Recessive Polycystic Kidney Disease · Perspectives on Drug Development in Early ADPKD · Current Challenges and ...

Drug Development in Autosomal Dominant Polycystic Kidney Disease

PHENOTYPIC VARIABILITY AND UTILITY OF. ENRICHING BIOMARKERS IN ADPKD CLINICAL. TRIALS. ADPKD has several unique features to consider during drug development.

Drug repurposing in autosomal dominant polycystic kidney disease

In this review, we focus on the repurposing approaches to identify suitable drug candidates to treat autosomal dominant polycystic kidney disease.

Emerging therapies for autosomal dominant polycystic kidney ...

Overwhelming evidence supports the central role of cAMP in ADPKD, possibly by promoting cyst initiation and most definitely by stimulating proliferation of the ...

Drug repurposing in autosomal dominant polycystic kidney disease

Advantages over de novo drug development are lower risk of failure, ... slow kidney cyst growth in patients with early-stage ADPKD. (GFR $70 ...

PKDOC Summit Defines Future of PKD Treatments

Drug Development in Cystic Kidney Disease ... This article summarizes the PKDOC Summit and where treatments currently stand for ARPKD and ADPKD.

Real-life use of tolvaptan in ADPKD: a retrospective analysis of a ...

... first disease-modifying drug proven to slow eGFR decline in high-risk patients with ADPKD. However, barriers from the patient perspective to ...

Drug Development in Autosomal Dominant Polycystic Kidney Disease

An ideal therapeutic intervention in ADPKD might be described as an agent that blocks formation and/or growth of cysts at an early stage of life with maximal ...

Four PKD Reports Published in CJASN - Critical Path Institute

Drug Development for Cystic Kidney Diseases · Perspectives on Drug Development in Autosomal Recessive Polycystic Kidney Disease · Perspectives on Drug Development ...

Drug repurposing in autosomal dominant polycystic kidney disease

In this review, we focus on the repurposing approaches to identify suitable drug candidates to treat autosomal dominant polycystic kidney disease.

Computational drug discovery approaches identify mebendazole as ...

Using transcriptomic and machine-learning drug discovery approaches, we predicted a number of existing drugs which may have therapeutic potential in ADPKD, and ...

Polycystic Kidney Disease Drug Development: A Conference Report

Currently, only one drug (Tolvaptan) has been approved by regulatory agencies as disease-modifying therapy for ADPKD, but given its mechanism of ...